Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Both semaglutide and tirzepatide are associated with improvements in quality of life for adults with obesity, though ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of ...

Once-weekly semaglutide 2.4 mg reduced the risk for major adverse cardiovascular events among adults with overweight or obesity who were at risk for atherosclerotic cardiovascular disease, according ...

Semaglutide therapy was associated with higher likelihood of passing low-risk cardiovascular thresholds among patients with ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Tirzepatide, semaglutide, and liraglutide lead to weight loss in adults with obesity and T1D over 1 year; the greatest weight ...

Shares of Novo Nordisk fell sharply on Monday after the company announced that a high-profile trial testing whether its oral ...

Novo Nordisk's older semaglutide version didn't meet expectations in trials to slow Alzheimer's cognitive decline. This ...